Longeveron Selects Clinical Research Organization for Phase 2 Alzheimer’s Trial

 Longeveron (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced the selection of Biorasi LLC (“Biorasi”) as its clinical research organization (CRO) to help conduct its Phase 2 clinical trial evaluating Lomecel-B infusion in Alzheimer’s Disease (AD) subjects.   

 

Biorasi has extensive experience in the management and execution of neurology clinical studies, with deep experience in phase I through IV trials, both in the US and globally.

https://www.biospace.com/article/releases/longeveron-selects-clinical-research-organization-for-phase-2-alzheimer-s-disease-trial/